Med eTrax (and BioSensors) on AHSN stand at Health and Care Innovation Expol 2016 at Manchester Central

Mede TraX is a patient monitoring solution which provides effective alerting, so that clinical teams are alerted to any changes in a patient’s condition which can be escalated to appropriate staff including the emergency teams. It is also the core module for other innovative technologies being produced by its subsidiary –  BioSensors – which will provide a range of non-invasive transdermal wireless sensors measuring bio-chemical markers.

The benefits

Med eTraX is currently used in six NHS organisations including Alder Hey Children’s Hospital, benefitting an estimated total of over one million patients.

The system increases accuracy in observations; significantly reduces unplanned transfers to ITU; and reduces overall mortality by between 11 and 15 per cent. It also enables observations to be carried out on time and more frequently.

Reducing the average length of hospital stay by 18 per cent reduces the cost of each stay by £750.

A 2009 NCEPOD study revealed poor communication between clinical teams was a key factor in 13.5 per cent of studied deaths. In a quarter of cases, a clinically important delay in the first review by a consultant was highlighted as an issue.

The integrated alerting application within Med eTraX provides automated alerts; patient location; clinical details; Early Warning Score information; patient history charts.

Blood monitoring sensor provides real time results

The company providing the system, Med eTrax Ltd, has been supported by the Innovation Agency, the AHSN for the North West Coast who brought the company and its partners together. It has received SBRI funding to develop an exciting related technology – a small wireless sensor to read defined signs of disease or abnormalities in the blood, without breaking the skin. This is in partnership with Liverpool John Moores University, BioSensors Ltd and Alder Hey Children’s Hospital.

The sensor will dramatically reduce the risk of infection and make blood tests less distressing for patients, especially babies and children and their families. Providing clinicians with real time trends, reducing time and increasing the effectiveness of any medications needed.

A functioning prototype is being developed which uses electromagnetic waves to measure blood lactate and haemoglobin levels initally, important indicators of the wellbeing of the patient. The sensor transmits the findings to Med eTrax, and its integrated early warning system alerts medical staff to any changes in a patient’s condition, allowing them to track progress in real time, without the need to wait for test results. Clinical trials are due to start in late 2016.

For more information: John Hopkins on 0151 705 3485

john.hopkins@medetrax.com

www.medetrax.com

Recent Posts